Tolerance and efficacy of off-label anti-interleukin-1 treatments in France: a nationwide survey

Table 4 Canakinumab efficacy (used in 25 patients)

Disease	Patient no.	First anti–IL-1	Dose and frequency	Clinical response	Treatment duration (d)	Associated treatment	CCS	DMARDs	Still treated
AOSD	1	No	150 mg/4 wk	No	148	No	No	No	No
AoSD	2	No	150 mg/8 wk	Total	31	Yes	Yes	No	Yes
sJIA	3	No	4 mg/kg/4 wk	Partial	61	Yes	Yes	Yes	No
sJIA	4	No	150 mg/8 wk	Total	499	UK	UK	UK	No
sJIA	5	No	150 mg/4 wk	No	31	Yes	Yes	Yes	No
sJIA	6	No	4 mg/kg/4 wk	Partial	28	Yes	Yes	No	No
sJIA	7	No	3 mg/Kg/4 wk	No	28	Yes	Yes	No	No
sJIA	8	No	4 mg/kg/4 wk	No	28	Yes	Yes	No	No
sJIA	9	Yes	4 mg/kg/4 wk	Partial	538	Yes	Yes	Yes	No
FMF	10	No	2 mg/kg/8 wk	Partial	731	Yes^#	No	No	Yes
FMF	11	No	2 mg/kg/8 wk	Partial	1151	Yes^#	No	No	Yes
FMF	12	No	2 mg/kg/8 wk	Total	589	Yes^#	No	No	Yes
FMF	13	Yes	2 mg/Kg on demand	Total	966	Yes^#	No	No	Yes
MKD	14	Yes	2 mg/kg/8 wk	Partial	802	Yes	Yes	No	Yes
MKD	15	Yes	2-3* mg/kg/8 wk	Partial	1112	No	No	No	Yes
MKD	16	No	3 mg/kg/8 wk	Total	1101	UK	UK	UK	Yes
MKD	17	No	2 mg/kg/8 wk	Total	957	No	No	No	Yes
MKD	18	No	7 mg/kg/8 wk	Partial	558	Yes**	No	No	Yes
MKD	19	No	3.5 mg/kg/8 wk	Total	163	UK	UK	UK	Yes
Vasculitis	20	No	150 mg/8 wk	Partial	181	Yes	Yes	No	No
Vasculitis	21	No	150 mg/8 wk	UK	UK	UK	UK	UK	No
Schnitzler’s syndrome	22	No	150 mg/8 wk	Partial	385	No	No	No	Yes
TRAPS	23	No	2 mg/kg/4 wk	Total	170	Yes***	No	No	Yes
Erdheim Chester	24	No	2 mg/kg/8 wk	Partial	679	Yes	Yes	No	Yes
Blau syndrome	25	No	150 mg/8 wk	Total	390	Yes	Yes	No	Yes

AOSD: adult onset Still’s disease; sJIA: systemic juvenile idiopathic arthritis; FMF: familial Mediterranean fever; MKD: mevalonate kinase deficiency, Vasculitis: giant cell arteritis (2) and polyarteritis nodosa (2), TRAPS: tumor necrosis factor receptor-associated periodic syndrome.
^#FMF: all patients received colchicine with canakinumab.
*MKD patient no. 15: initial dose 2 mg/kg, then augmented to 3 mg/Kg.
*MKD patient no. 18: adalimumab was associated at the time of canakinumab onset.
***TRAPS: enalapril was given with canakinumab.
CCS: corticosteroids.

ISSN: 1750-1172